BACKGROUND: @entity302 is one of the most common neurological conditions in @entity235 . Despite that @entity302 appears to be common in the Rottweiler breed, published literature about the phenotype of @entity302 in this breed is lacking. The aim of this questionnaire-based study was to describe the clinical characteristics of @entity302 in the Rottweiler breed including; signalment, pedigree, housing conditions and information about the @entity410 such as age at onset, @entity410 type, duration, and progression, as well as number of @entity410 days (24 h), effect and side effects of anti- @entity302 drugs, and potential comorbidities. The diagnosis for @entity302 of unknown origin was based on the following inclusion criteria: >= 2 @entity410 days, starting between 6 months and 7 years of age, no known history of @entity4968 or serious @entity542 , and (when available), pre-study routine serum biochemical parameters were within the reference intervals. RESULTS: A total of 37 cases (23 females and 14 males) were included in the study. The median age at onset of @entity410 was 36 months (range 8-84 months). The @entity235 suffered from generalized @entity410 , and more than 50 % of the @entity235 had experienced @entity410 (>1 @entity410 in 24 h). The @entity235 commonly started to @entity410 while resting (23/36) and/or sleeping (20/36). Only 3 of the 36 @entity235 experienced @entity410 during activities such as walking or training. All of the 24/37 (64.9 %) dogs on antiepileptic drugs received @entity109 . Five @entity235 needed add-on treatment (n = 5), and of these: one @entity235 was on 3 drugs ( @entity109 , @entity972 bromid and @entity4677 ) (n = 1), three @entity235 were on @entity109 and @entity27801 (n = 3), and one @entity235 received @entity109 and imepitoin (n = 1). @entity410 frequency did not necessarily improve following antiepileptic treatment, and for six of 21 (28.6 %) of the @entity235 , @entity410 frequency increased. All of the Rottweilers in this study had relatives with @entity302 reported. CONCLUSIONS: The Rottweilers suffering from @entity302 in this study presented with generalized @entity410 , and their response to antiepileptic treatment was variable. More than 50 % of the @entity235 had experienced @entity410 (>1 @entity410 in 24 h).

Clinical characteristics of XXXX of unknown origin in the Rottweiler breed.

@entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures', 'Seizure', 'cluster seizures', 'tonic-clonic seizures'] @entity4677 :: ('MESH:C026098', 'Chemical') :: ['levetiracetam'] @entity235 :: ('9615', 'Species') :: ['dog', 'dogs'] @entity542 :: ('MESH:D006259', 'Disease') :: ['head trauma'] @entity4968 :: ('MESH:D011041', 'Disease') :: ['poisoning'] @entity27801 :: ('MESH:C039004', 'Chemical') :: ['potassium bromide'] @entity109 :: ('MESH:D010634', 'Chemical') :: ['phenobarbital'] @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptic', 'epilepsy', 'Epilepsy'] @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium']
@entity302 :: (MESH:D004827,Disease) :: ['epilepsy']
